Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum-based quadruple probiotic
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum-based quadruple probiotic is a microbial therapy consisting of a combination of four probiotic strains, including *Lactobacillus plantarum*. This formulation has been investigated by researchers at West China Hospital, Sichuan University, for its potential to alleviate Low Anterior Resection Syndrome (LARS) in patients undergoing surgery for rectal cancer. LARS is a collection of symptoms, such as fecal urgency, increased bowel frequency, and incontinence, that frequently occur after low anterior resection. The probiotic mixture is designed to modulate the gut microbiota, restore intestinal barrier function, and reduce postoperative inflammation, thereby improving bowel function and the overall quality of life for patients. While some clinical records for the associated trial (ChiCTR1900021090) list a quadruple probiotic containing *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*, the *Lactobacillus plantarum*-based variant is specifically identified in related clinical research contexts for the same indication.
- Other names
- quadruple probioticquadruple probiotics
Beyond the preview
Go deeper on Lactobacillus plantarum-based quadruple probiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum-based quadruple probiotic.